Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track

05/06

UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.

The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1174571892"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174571892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174571892?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174571892","market":"sg","top_or_hot":-1,"title":"Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth","media":"Stock Track","content":"<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-06 21:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"烏龍製藥","start_time":0,"source_url":"","article_id":"1174571892","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174571892","pubTimestamp":1778073147,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|UroGen Pharma盘前飙升5.67%，Q1盈利强劲，营收增长152%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}